Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 296 entries
View as:

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01075048 Org: User:
Start: 01/26/10 End: 02/20/15 Due: 02/20/16

Welchol as Monotherapy for Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00789737 Org: User:
Start: 01/31/09 End: 12/31/11 Due: 12/31/12

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT00616733 Org: User:
Start: 03/31/08 End: 09/30/10 Due: 09/30/11

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT01349049 Org: User:
Start: 11/21/11 End: 01/09/18 Due: 01/09/19

Treatment of Pain Associated With Fibromyalgia

Phase: N/A Priority: Normal
NCT ID: NCT02187159 Org: User:
Start: 11/30/14 End: 07/07/16 Due: 07/07/17

Study of Single-dose DS-3201b in Participants With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT04276662 Org: User:
Start: 11/21/19 End: 02/23/21 Due: 02/23/22

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Phase: N/A Priority: Normal
NCT ID: NCT06819007 Org: User:
Start: 03/19/25 End: 01/31/32 Due: 01/31/33

A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation

Phase: N/A Priority: Normal
NCT ID: NCT05804747 Org: User:
Start: 02/16/23 End: 12/01/25 Due: 12/01/26

DX-8951f in Treating Patients With Metastatic Stomach Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00017212 Org: User:
Start: 04/30/01 End: 09/30/03 Due: 09/30/04

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Phase: N/A Priority: Normal
NCT ID: NCT06809764 Org: User:
Start: 02/21/25 End: 02/12/27 Due: 02/12/28

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

Phase: N/A Priority: Normal
NCT ID: NCT06975371 Org: User:
Start: 04/14/25 End: 06/20/25 Due: 06/20/26

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT02668653 Org: User:
Start: 09/01/16 End: 06/16/23 Due: 06/16/24

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01217229 Org: User:
Start: 03/03/11 End: 04/26/12 Due: 04/26/13

DX-8951f in Treating Patients With Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00004108 Org: User:
Start: 09/30/99 End: 04/30/05 Due: 04/30/06

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT02004678 Org: User:
Start: 09/30/13 End: 10/31/13 Due: 10/31/14

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00521404 Org: User:
Start: 08/15/07 End: 08/20/10 Due: 08/20/11

Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01364844 Org: User:
Start: 07/31/11 End: 11/30/13 Due: 11/30/14

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Phase: N/A Priority: Normal
NCT ID: NCT03291288 Org: User:
Start: 02/26/18 End: 04/16/21 Due: 04/16/22

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04635111 Org: User:
Start: 01/07/21 End: 03/01/36 Due: 03/01/37

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06040593 Org: User:
Start: 07/31/23 End: 02/23/24 Due: 02/23/25

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Phase: N/A Priority: Normal
NCT ID: NCT06362252 Org: User:
Start: 07/22/24 End: 12/30/26 Due: 12/30/27

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

Phase: N/A Priority: Normal
NCT ID: NCT02647320 Org: User:
Start: 01/31/16 End: 01/31/17 Due: 01/31/18

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01049893 Org: User:
Start: 01/31/10 End: 11/30/11 Due: 11/30/12

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

Phase: N/A Priority: Normal
NCT ID: NCT01956305 Org: User:
Start: 09/30/13 End: 06/30/14 Due: 06/30/15

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Phase: N/A Priority: Normal
NCT ID: NCT06330064 Org: User:
Start: 04/10/24 End: 07/25/28 Due: 07/25/29